Clinical Report: New Tool Sharpens Leukemia Workup

Overview

A prospective study evaluated optical genome mapping (OGM) as a first-line test in adult acute leukemia diagnostics, demonstrating high specificity and sensitivity. OGM identified significantly more reportable variants compared to traditional methods, enhancing diagnostic classification and risk stratification.

Background

Accurate diagnosis and risk assessment in acute leukemia are critical for effective treatment planning. Current cytogenetic methods, including karyotyping and FISH, have limitations that can lead to missed abnormalities. OGM offers a promising alternative by providing genome-wide detection of structural variants, potentially improving patient outcomes.

Data Highlights

Key Findings

• OGM identified 640 reportable variants compared to 444 by karyotype and FISH.
• 25% of variants detected by OGM were classified as tier 1A in clinical significance.
• OGM provided additional clinically relevant findings in 109 cases, influencing diagnostic classification or risk stratification.
• Turnaround times for OGM were approximately 9 days for preliminary reports and 13 days for final reports.
• Missed findings with OGM were primarily low-level aneuploidies, which did not affect diagnosis.

Clinical Implications

The integration of OGM into existing diagnostic workflows can enhance the detection of clinically relevant genomic alterations in acute leukemia. Clinicians should consider OGM as a complementary tool alongside traditional cytogenetic methods to improve diagnostic accuracy and patient management.

Conclusion

OGM represents a significant advancement in the diagnostic workup of acute leukemia, with the potential to refine classification and risk assessment. Its implementation may lead to better patient outcomes through more precise genomic characterization.

References

1. The ASCO Post, 2025 -- Preclinical Leukemia Chip Platform Improves Evaluation of CAR T-Cell Therapies
2. The ASCO Post, 2026 -- AI-Powered, Next-Generation Sequencing Blood-Based Assay Evaluated for Detection of Post-HCT Relapse in AML and MDS
3. Blood Cancer Journal, 2017 -- An Innovative Method for Identifying Effective Combination Treatments in Primary Human Acute Myeloid Leukemia Samples
4. Genetic risk classification for adults with AML receiving less-intensive therapies: the 2024 ELN recommendations | Blood | American Society of Hematology
5. Comparison of Optical Genome Mapping With Conventional Diagnostic Methods for Structural Variant Detection in Hematologic Malignancies - PubMed
6. The ASCO Post — Blood Tests Could Help Predict Which Patients With Lymphoma May Respond Poorly to CAR T-Cell Therapy
7. Genetic risk classification for adults with AML receiving less-intensive therapies: the 2024 ELN recommendations | Blood | American Society of Hematology
8. Comparison of Optical Genome Mapping With Conventional Diagnostic Methods for Structural Variant Detection in Hematologic Malignancies - PubMed